Currently, four PHD inhibitors i.e. FG4592 (Roxadustat) from FibroGen, GSK1278863 (Daprodustat) from GlaxoSmithKline, Bay85-3934 (Molidustat) from Bayer and AKB-6548 (Vadadustat) from Akebia are in clinical use or trials for anaemia treatment in patients with chronic kidney disease (CKD)5,6. Here, PDC is linked to chronic kidney disease.